Posterity Health, a leader in male reproductive and hormonal health, has successfully raised $13 million in a Series A funding round aimed at expanding access to comprehensive care for men across the U.S. The investment was spearheaded by Georgetown Equity Partners, with contributions from existing backers FCA Venture Partners, Distributed Ventures, and WVV, as well as new investors SteelSky Ventures, Scrub Capital, and other key players in digital health.
The company provides innovative solutions designed to address male fertility issues, optimize hormone levels, and manage long-term health risks. By combining cutting-edge technology with expert clinical care, Posterity Health has become a trusted resource for men at every stage of life—from family building and fertility optimization to hormone management, vasectomy procedures, low-testosterone treatments, and more. Through a blend of telehealth services, at-home diagnostics, and in-person care, Posterity Health aims to revolutionize male reproductive health.
Approximately 50% of all infertility cases are linked to male factors, yet traditional healthcare models often delay male evaluations for up to two years. This delay results in unnecessary treatments, missed diagnoses, and increased healthcare costs. Posterity Health’s platform addresses these challenges by providing faster, more effective interventions and making specialized care more accessible.
Key challenges in male reproductive health, which Posterity Health is working to overcome, include:
Delayed Diagnoses & High Costs – Couples struggling with infertility often wait years before evaluating the male partner, leading to increased expenses and unnecessary procedures. Posterity Health offers personalized insights that allow for earlier detection and quicker intervention, reducing both costs and stress for couples.
Limited Access to Specialists – With only 250 fellowship-trained reproductive urologists in the country, many men face long wait times or geographic barriers. Posterity Health uses technology to optimize the match between patients and specialists, ensuring timely, evidence-based care.
Overprescription & Mismanagement of Testosterone Therapy – Improper hormone management can negatively affect fertility, yet testosterone therapies are frequently prescribed without adequate oversight. Posterity Health’s advanced decision-support tools help ensure hormone treatments follow clinical guidelines, safeguarding male fertility.
Undiagnosed Health Risks – Male infertility is linked to serious conditions like testicular cancer, obesity, and high blood pressure. Early evaluation can lead to early detection of these risks, prompting preventive measures that can significantly improve long-term health outcomes.
Dr. William Schoolcraft, a global fertility expert, has been appointed as a strategic advisor to Posterity Health. Dr. Schoolcraft, recognized for his pioneering work in IVF and sperm quality optimization, will lead initiatives to educate both clinicians and the public on the importance of early male fertility evaluations.
With its innovative platform and nationwide reach, Posterity Health is positioned to lead a new era in male fertility and hormone care. Employers, payers, and health systems are increasingly recognizing the cost-saving and health-improving potential of early male fertility intervention, making Posterity Health an essential partner in the field.
The Series A funding will allow the company to expand its platform and continue delivering high-quality reproductive care to men across the country. As male reproductive health becomes an increasingly important area of focus, Posterity Health is committed to helping men take an active role in their reproductive health and overall well-being.
Related topics:
Ethical Concerns Raised Over IVF in Light of Trump’s Executive Order
Inflammation and Metabolic Syndrome Linked to Prostate Enlargement in Aging Men
Possible CMV Transmission via Intrauterine Insemination: A Case Study
